Patents Assigned to Pfizer
  • Pharmaceutical composition for the treatment of CNS and other disorders
    Publication number: 20030119837
    Abstract: The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant &agr;7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant &agr;7 nicotinic receptor agonist.
    Type: Application
    Filed: August 28, 2002
    Publication date: June 26, 2003
    Applicant: Pfizer Inc.
    Inventors: Brian Thomas O'Neill, Jotham Wadsworth Coe, Christopher J. O'Donnell
  • METHODS FOR PREPARING SODIUM-HYDROGEN EXCHANGER TYPE-1 INHIBITORS
    Publication number: 20030119873
    Abstract: This invention relates to methods of preparing sodium-hydrogen exchanger type 1 (NHE-1) inhibitors of formula I′ 1
    Type: Application
    Filed: December 16, 2002
    Publication date: June 26, 2003
    Applicant: Pfizer Inc.
    Inventors: Frank R. Busch, Gregory J. Withbroe
  • Crystalline forms of macrolide antibiotic
    Patent number: 6583274
    Abstract: Novel crystalline forms of a compound of Formula 1 are disclosed: Also disclosed are pharmaceutical compositions comprising these forms, and methods of their preparation and use.
    Type: Grant
    Filed: May 2, 2000
    Date of Patent: June 24, 2003
    Assignee: Pfizer Inc.
    Inventors: Douglas J. M. Allen, Barry J. Morton, Robert J. Rafka, Colman B. Ragan
  • Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
    Publication number: 20030114503
    Abstract: The present invention relates to a method of treating cancer in a mammal, including a human, by administering to the mammal a FTase inhibitor in combination with an HMG CoA reductase inhibitor.
    Type: Application
    Filed: August 12, 2002
    Publication date: June 19, 2003
    Applicant: Pfizer Inc.
    Inventor: Shama Mohammed Kajiji
  • Canine peroxisome proliferator activated receptor gamma
    Publication number: 20030113815
    Abstract: This invention provides polynucleotides encoding canine peroxisome proliferator activated receptor gamma polypeptides, canine peroxisome proliferator activated receptor gamma polypeptides, vectors comprising polynucleotides encoding canine peroxisome proliferator activated receptor gamma polypeptides, transformed cells comprising polynucleotides encoding canine peroxisome proliferator activated receptor gamma polypeptides, antibodies which specifically binds to canine peroxisome proliferator activated receptor gamma polypeptides, microarrays comprising polynucleotides encoding canine peroxisome proliferator activated receptor gamma and therapeutic methods related thereto.
    Type: Application
    Filed: December 18, 2002
    Publication date: June 19, 2003
    Applicant: Pfizer Inc.
    Inventors: Karen L. Houseknecht, Pamela J. Steele, Yongling Xiao
  • Enantiomers of 6-[(4-chloro-phenyl)- hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1- methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
    Publication number: 20030114487
    Abstract: This invention relates to the enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-y)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl) -phenyl]-1-methyl-1H-quinolin-2-one, prodrugs thereof, and pharmaceutically acceptable salts and solvates of said compounds and said prodrugs, that are useful in the treatment of hyperproliferative diseases, such as cancers, in mammals. The invention also relates to processes for the production of enantiomerically pure or optically enriched (+)- or (−)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl )-phenyl]-1 -methyl-1H-quinol in-2-one enantiomers from a mixture containing two enantiomers using continuous chromatography.
    Type: Application
    Filed: August 27, 2002
    Publication date: June 19, 2003
    Applicant: Pfizer Inc.
    Inventors: R. Mark Guinn, Subramanian Sam Guhan, Karl K. Ng, Derek L. Tickner, Marcus Douglas Ewing, Clifford N. Meltz, Bryan Li, Kees Pouwer
  • Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
    Publication number: 20030114439
    Abstract: The present invention relates to methods of treating various CNS and other disorders by adminstering fluoroalkoxybenzylamino derivatives of nitrogen containing heterocyclic compounds, and specifically, by administering compounds of the formula 1
    Type: Application
    Filed: July 29, 2002
    Publication date: June 19, 2003
    Applicant: Pfizer Inc.
    Inventors: Phillip Branch Chappell, Brian Thomas O'Neill, Mario David Saltarelli
  • Pyrimidine-2,4,6-trione metalloproteinase inhibitors
    Patent number: 6579982
    Abstract: The present invention relates to pyrimidine-2,4,6-trione metalloproteinase inhibitors of the formula wherein X, Y, Ar1, Z, R1, R2 and R3 are as defined in the specification, and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: June 17, 2003
    Assignee: Pfizer Inc.
    Inventor: Julian Blagg
  • Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
    Patent number: 6579887
    Abstract: The present invention relates to compounds of formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11 are as defined herein. The above compounds of formula 1 are useful in the treatment of hyperproliferative disorders, such as cancer, in mammals.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: June 17, 2003
    Assignee: Pfizer Inc
    Inventors: Joseph P. Lyssikatos, Susan D. La Greca
  • Compositions having improved bioavailability
    Patent number: 6579898
    Abstract: A composition comprising eletriptan and a p-glycoprotein (p-gp) inhibitor useful for the treatment of migraine. The bioavailability of eletriptan can be increased by co-administering eletriptan with a p-gp inhibitor. The eletriptan and p-gp inhibitor can be administered together in a composition or as separate components. If administered separately, they can be embodied as a kit. Also provided is a method of treating migraine using said composition or sequential administration of components.
    Type: Grant
    Filed: February 13, 2002
    Date of Patent: June 17, 2003
    Assignee: Pfizer Inc.
    Inventor: Michael John Humphrey
  • Pyridazinone aldose reductase inhibitors
    Patent number: 6579879
    Abstract: The present invention relates to novel pyridazinone compounds, pharmaceutical compositions comprising those compounds and to methods of using such compounds and compositions to inhibit aldose reductase, lower sorbitol levels and, thus, lower fructose levels, and/or treat or prevent diabetic complications such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic microangiopathy and diabetic macroangiopathy in mammals. This invention also relates to methods of affording cardioprotection to subjects not suffering from diabetes. This invention also relates to pharmaceutical compositions and kits comprising a combination of an aldose reductase inhibitor (ARI) of this invention and a sorbitol dehydrogenase inhibitor and to methods of using such compositions or kits to treat or prevent the above diabetic complications in mammals.
    Type: Grant
    Filed: March 21, 2002
    Date of Patent: June 17, 2003
    Assignee: Pfizer Inc
    Inventor: Banavara L. Mylari
  • Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof
    Publication number: 20030109516
    Abstract: The present invention relates to tetrahydroquinazoline-2,4-diones derivatives of the formula (I): 1
    Type: Application
    Filed: January 10, 2003
    Publication date: June 12, 2003
    Applicant: Pfizer Inc.
    Inventors: Anton Franz Joseph Fliri, Todd William Butler, Randal James Gallaschun, John Anthony Ragan, Brian Patrick Jones
  • Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
    Publication number: 20030109544
    Abstract: Pharmaceutical compositions are disclosed for the treatment of nicotine dependence or addiction, tobacco dependence or addiction, reduction of nicotine withdrawal symptoms or aiding in the cessation or lessening of tobacco use or substance abuse. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an anti-depressant or anxiolytic agent and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.
    Type: Application
    Filed: January 21, 2003
    Publication date: June 12, 2003
    Applicant: Pfizer Inc.
    Inventors: Edmund P. Harrigan, Jotham W. Coe, Brian T. O'Neill, Steven B. Sands, Eric Jacob Watsky
  • One dose vaccination with mycoplasma hyopneumoniae
    Publication number: 20030109473
    Abstract: The present invention relates to methods for treating or preventing a disease or disorder in an animal caused by infection by Mycoplasma hyopneumoniae (M. hyo) by administering to the animal at approximately three (3) to ten (10) days of age, a single dose of an effective amount of a M. hyo vaccine. The M. hyo vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine. The M. hyo vaccine administered in accordance with the present invention can be synthesized or recombinantly produced.
    Type: Application
    Filed: June 19, 2002
    Publication date: June 12, 2003
    Applicant: Pfizer Inc.
    Inventors: Robin Lee Keich, Lisa Grace Sabbadini
  • Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors
    Patent number: 6576653
    Abstract: This invention relates to compounds of Formula I or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof or a pharmaceutically acceptable salts of the prodrugs. This invention also relates to pharmaceutical compositions comprising a compound of Formula I, and to methods of treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, or tissue ischemia.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: June 10, 2003
    Assignee: Pfizer Inc.
    Inventor: Daisy Joe Du Bois
  • C-4?-substituted macrolide derivatives
    Patent number: 6576749
    Abstract: Compounds are of the formula: and to pharmaceutically acceptable salts thereof. The compounds of formula 1 are potent antibacterial agents that can be used to treat various bacterial infections and disorders related to such infections. The invention also relates to pharmaceutical compositions including the compounds of formula 1 and to methods of treating bacterial infections by administering the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1 and to intermediates useful in such preparation.
    Type: Grant
    Filed: February 26, 2002
    Date of Patent: June 10, 2003
    Assignee: Pfizer Inc.
    Inventors: Brian Scott Bronk, Takushi Kaneko, Michael Anthony Letavic, Hengmaio Cheng, Edward Alan Glazer, Bingwei Vera Yang
  • Biaryl compounds useful as anticancer agents
    Patent number: 6576632
    Abstract: The present invention relates to compounds of formula I and to pharmaceutically acceptable salts, hydrates and prodrugs thereof, wherein R1, R2, R3, R4, R5, R10, R11, b, m, n, p and v are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and methods of treating hyperproliferative disorders in mammals by administering the above compounds.
    Type: Grant
    Filed: April 13, 2000
    Date of Patent: June 10, 2003
    Assignee: Pfizer Inc
    Inventors: Steven W. Goldstein, Kelly P. Longo, James F. Blake, Mohamed M. A. Awad, Kenneth P. Raiche, Kevin W. Kramer
  • Alkylamide compounds
    Publication number: 20030105097
    Abstract: The invention provides compounds of formula (I) 1
    Type: Application
    Filed: May 6, 2002
    Publication date: June 5, 2003
    Applicant: Pfizer Inc.
    Inventors: Andrew Simon, Alan Stobie
  • Disruption of the prostaglandin E synthase 2 gene
    Publication number: 20030106085
    Abstract: The present invention features genetically-modified non-human mammals and animal cells containing a disrupted prostaglandin E synthase 2 gene as well as methods of treating an inflammation-mediated disorder involving administering an agent that inhibits prostaglandin E synthase 2.
    Type: Application
    Filed: November 13, 2002
    Publication date: June 5, 2003
    Applicant: Pfizer Inc.
    Inventors: Laurent P. Audoly, Omar L. Francone, Mehrdad Haghpassand, John E. Hambor, Marsha L. Roach, Jeffrey L. Stock
  • Functional assay for agonist activation of receptors
    Publication number: 20030104489
    Abstract: The invention provides a novel high throughput functional assay for certain agonist-activated receptors, including Alpha 1A, Alpha 2A, H1, 5HT1A, 5HT2A, D2 and D3 receptors. The assay method of the invention uses an elevated temperature and a cell line that stably expresses both the receptor and the promiscuous G protein G↑15 wherein agonist-induced intracellular Ca2+ release was monitored by a Fluorometric Imaging Plate Reader (FLIPR). The magnitude of the agonist-induced response was dramatically enhanced by performing the assay at an elevated temperature, rather than at room temperature. The novel assay of the invention is useful for selecting compounds which are effective in the treatment of disorders related to the activation of certain neuroreceptors.
    Type: Application
    Filed: November 7, 2002
    Publication date: June 5, 2003
    Applicant: Pfizer Inc.
    Inventors: Stephen Wong, Alka Shirikhande